- Home
- MGLD vs CELU Comparison
MGLD vs CELU Comparison
Compare MGLD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- CELU
- Stock Information
- Founded
- MGLD 1996
- CELU 2016
- Country
- MGLD United States
- CELU United States
- Employees
- MGLD N/A
- CELU N/A
- Industry
- MGLD Finance/Investors Services
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- CELU Health Care
- Exchange
- MGLD Nasdaq
- CELU Nasdaq
- Market Cap
- MGLD 36.5M
- CELU 37.7M
- IPO Year
- MGLD N/A
- CELU N/A
- Fundamental
- Price
- MGLD $0.91
- CELU $2.29
- Analyst Decision
- MGLD
- CELU
- Analyst Count
- MGLD 0
- CELU 0
- Target Price
- MGLD N/A
- CELU N/A
- AVG Volume (30 Days)
- MGLD 5.0K
- CELU 88.7K
- Earning Date
- MGLD 05-08-2025
- CELU 05-08-2025
- Dividend Yield
- MGLD N/A
- CELU N/A
- EPS Growth
- MGLD N/A
- CELU N/A
- EPS
- MGLD N/A
- CELU N/A
- Revenue
- MGLD $31,205,000.00
- CELU $54,220,000.00
- Revenue This Year
- MGLD N/A
- CELU $23.29
- Revenue Next Year
- MGLD N/A
- CELU N/A
- P/E Ratio
- MGLD N/A
- CELU N/A
- Revenue Growth
- MGLD N/A
- CELU 138.11
- 52 Week Low
- MGLD $0.70
- CELU $1.00
- 52 Week High
- MGLD $2.10
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- MGLD 50.13
- CELU 62.18
- Support Level
- MGLD $0.85
- CELU $1.90
- Resistance Level
- MGLD $0.92
- CELU $2.11
- Average True Range (ATR)
- MGLD 0.07
- CELU 0.28
- MACD
- MGLD 0.00
- CELU 0.07
- Stochastic Oscillator
- MGLD 27.40
- CELU 75.73
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.